 BOSTON, MA ACCESSWIRE June 24, 2021 Pieris Pharmaceuticals, Inc. NASDAQ:PIRS , a clinical-stage biotechnology company advancing novel biotherapeutics through its proprietary Anticalin technology platform for respiratory diseases, cancer, and other indications, today announced that the U.S. Food and Drug Administration FDA has granted orphan drug designation to cinrebafusp alfa PRS-343, a 4-1BBHER2 bispecific, for the treatment of HER2-high and HER2-low expressing gastric cancers. The granting of orphan drug designation to cinrebafusp alfa underscores the high unmet medical need that persists in the treatment of gastric cancer and reinforces our conviction in the importance of developing this program while setting a high bar for success to help patients with limited therapeutic options, said Stephen S. 